Synergistic alignment of leading knowledge-based companies across bioprocesses, plasma fractionation, vaccines, and cell therapies under unified strategic governance.
Development and manufacturing of plasma-derived therapeutics and advanced biologics — producing Albumin, IVIG, Fibrinogen, and Factor VIII.
Expanding plasma-derived biomanufacturing, enhancing product diversification, and pioneering high-value strategic bio-therapeutics.
Human Albumin, Intravenous Immunoglobulin (IVIG), Fibrinogen, Factor VIII, and Advanced Biologics.
First node in the plasma therapeutics supply chain — collecting and procuring human plasma across eight active centers nationwide.
Continuous expansion of apheresis centers, integration of automated separation systems, and compliance with WHO and European standards.
Human Plasma Apheresis, Quality Assurance, Safe Cold-Chain Logistics, and Donor Network Management.
A decisive step toward national insulin self-sufficiency — developing production capacity for eight types of insulin and novel therapeutics.
High-yield recombinant insulin synthesis, automated aseptic cartridge and pen filling, and national supply chain resilience.
Recombinant Human Insulin, Insulin Glargine, Aspart, Lispro, and Advanced Diabetes Therapeutics.
Producing over 70% of Iran's demand for scorpion and snake antivenoms — with an active focus on regional export expansion.
Plasmid purification, modern fractionation of equine hyperimmune sera, and emergency biological antidote reserves.
Polyvalent Snake Antivenom, Scorpion Antivenom, Tetanus Antitoxin, and Diphtheria Antitoxin.
Leading accelerator and biotechnology hub — developing pharmaceutical molecules and strengthening the bridge between academia and industry.
Bioprocess design, cell bank establishment, pilot production, and seed investment for elite biotechnologists.
Monoclonal Antibodies, Recombinant Proteins, Biosimilars, and Tech Transfer.
Pioneering cell therapy in Iran — developing and manufacturing CAR-T cells and localizing advanced cellular therapies for diverse pathologies.
Autologous & allogeneic cell processing, viral vector gene delivery, and GMP-certified cleanroom cell expansion.
CAR-T Cell Therapy for Hematologic Cancers, Mesenchymal Stem Cells, and Advanced Cellular Immunotherapy.
Development and manufacturing of Papilloguard, Pneumoguard, and Zonaguard vaccines — fortifying national immunization infrastructure.
Recombinant virus-like particle (VLP) platforms, polysaccharide conjugate vaccine synthesis, and cold-chain vaccine logistics.
HPV Vaccine (Papilloguard), Pneumococcal Conjugate Vaccine (Pneumoguard), and Shingles Vaccine (Zonaguard).
Rahnab Pharmed direct communications desk is open to business inquiries, technology transfers, and collaborative ventures.